Genetron Health
Specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
Launch date
Employees
Market cap
€116m
Enterprise valuation
€93m (Public information from Mar 2024)
Share price
$4.025 GTH
Beijing China (HQ)
Financials
Estimates*
CNY | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 109m | 248m | 323m | 424m | 532m | 651m | 765m |
% growth | - | 127 % | 31 % | 31 % | 25 % | 22 % | 18 % |
EBITDA | (431m) | (233m) | (626m) | (3.0b) | (460m) | (546m) | - |
% EBITDA margin | (395 %) | (94 %) | (193 %) | (718 %) | (87 %) | (84 %) | - |
Profit | (453m) | (512m) | (676m) | (3.1b) | (496m) | (808m) | - |
% profit margin | (416 %) | (207 %) | (209 %) | (723 %) | (93 %) | (124 %) | - |
R&D budget | 49.3m | 78.6m | 91.7m | 149m | 254m | 290m | - |
R&D % of revenue | 45 % | 32 % | 28 % | 35 % | 48 % | 45 % | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | CNY50.0m | Series A | |
N/A | Series B | ||
N/A | N/A | Series C | |
$71.0m | Series D | ||
N/A | N/A | IPO | |
Total Funding | €70.8m |
Recent News about Genetron Health
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Genetron Health
EditACQUISITION by Genetron Health Oct 2023